Scientists are finding ways to use quantum effects to create groundbreaking thermal devices that can help cool electronic systems. The quantum thermal transistor is one of the most exciting innovations in this field. While the current works surrounding this device are still theoretical, recent advancements in the fabrication of qubits using quantum dots and superconducting circuits have created a growing sense of optimism.
A team of chemists at the Korea Advanced Institute of Science and Technology has succeeded in pulling an oxygen atom from a molecule and replacing it with a nitrogen atom. In their study, published in the journal Science, the group used photocatalysis to edit a furan in their lab.
CleanCo is reinforcing its commitment to Queensland’s clean energy future by exploring the potential to trial Australia’s largest grid-connected NAS® Battery Energy Storage System at the Swanbank Clean Energy Hub in Ipswich.
The partnership between Allset and CleanCo is a result of CleanCo’s proactive market engagement to identify emerging energy generation and storage technologies suitable for its Swanbank site. The parties will progress a feasibility study to finalise the engineering, procurement, and construction (EPC) agreement to support a final investment decision for the battery’s installation.
The Queensland University of Technology’s (QUT) Energy Storage Research Group will play a key role as the knowledge sharing partner, bringing a wealth of knowledge to the project, having commissioned Australia’s first NAS Battery in 2023.
The study is expected to be completed in early 2025 to support an investment decision in the same year, with the project potentially operational by mid-2026.
Scientists have discovered cannabidiol, a compound in cannabis known as CBD, in a common Brazilian plant, opening potential new avenues to produce the increasingly popular substance.
The team found CBD in the fruits and flowers of a plant known as Trema micrantha blume, a shrub which grows across…
Hiding in plain sight!
Researchers at Duke-NUS Medical School have identified interleukin-11 (IL11) as a key factor in the ageing process. Elevated IL11 levels lead to fat accumulation and muscle loss—two major indicators of ageing. Inhibiting IL11 could enhance healthy lifespans.
Ageing populations pose significant health and economic challenges globally. Even a one-year increase in life expectancy could be valued at $38 trillion.
In a study published in Nature, the team demonstrated that anti-IL11 therapy not only counters the harmful effects of ageing but also increases lifespan by up to 25% in preclinical models. The therapy shifts metabolism from generating harmful white fat to beneficial brown fat, which helps burn calories and maintain body temperature.
Qualcomm fixes 20 vulnerabilities, including actively exploited CVE-2024–43047 in DSP, urging fast OEM updates.
New Gorilla botnet launches over 300,000 DDoS attacks globally, exploiting IoT devices and Apache Hadoop flaws.
Organizations are losing between $94 — $186 billion annually to vulnerable or insecure APIs (Application Programming Interfaces) and automated abuse by bots. That’s according to The Economic Impact of API and Bot Attacks report from Imperva, a Thales company. The report highlights that these security threats account for up to 11.8% of global cyber events and losses, emphasizing the escalating risks they pose to businesses worldwide.
Drawing on a comprehensive study conducted by the Marsh McLennan Cyber Risk Intelligence Center, the report analyzes over 161,000 unique cybersecurity incidents. The findings demonstrate a concerning trend: the threats posed by vulnerable or insecure APIs and automated abuse by bots are increasingly interconnected and prevalent. Imperva warns that failing to address security risks associated with these threats could lead to substantial financial and reputational damage.
Google’s new security pilot in India automatically blocks sideloading of risky Android apps, protecting users from malicious installs.
A widely available and inexpensive antidepressant drug may soon save lives from an altogether different kind of disease.
The growth of the most aggressive and deadly brain cancer, glioblastoma, was effectively suppressed in both ex vivo human tissue samples and in living mice by an FDA approved serotonin modulator currently used to treat major depression.
It’s not a cure, but it may offer some relief and constitute an effective part of a treatment regime for glioblastoma patients. Human clinical trials are the next step; patients are cautioned against self-medicating at this stage.